J
Jeremy Ader
Researcher at Yale University
Publications - 6
Citations - 297
Jeremy Ader is an academic researcher from Yale University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 2, co-authored 3 publications receiving 259 citations.
Papers
More filters
Journal ArticleDOI
Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention
Nihar R. Desai,Steven M. Bradley,Craig S. Parzynski,Brahmajee K. Nallamothu,Paul Chan,John A. Spertus,Manesh R. Patel,Jeremy Ader,Aaron Soufer,Harlan M. Krumholz,Jeptha P. Curtis +10 more
TL;DR: Since the publication of the Appropriate Use Criteria for Coronary Revascularization in 2009, there have been significant reductions in the volume of nonacute PCI and the proportion ofNonacute PCIs classified as inappropriate has declined, although hospital-level variation in inappropriate PCI persists.
Journal ArticleDOI
The medical home and integrated behavioral health: advancing the policy agenda.
Jeremy Ader,Christopher J. Stille,David M. Keller,Benjamin F. Miller,Michael S. Barr,James M. Perrin +5 more
TL;DR: This article presents recommendations to build demonstration projects to test existing approaches of integration, develop interdisciplinary training programs to support members of the integrated care team, implement population-based strategies to improve behavioral health, eliminate behavioral health carve-outs and test innovative payment models.
Journal ArticleDOI
Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial.
Samuel W. Reinhardt,Nihar R. Desai,Yuanyuan Tang,Philip Jones,Jeremy Ader,John A. Spertus,John A. Spertus +6 more
TL;DR: In this paper, the authors used patient-level data to develop multivariable models to predict the risk for stroke or systemic embolism and for major bleeding including all three treatment groups (dabigatran 110mg, dabigatrans 150mg, and warfarin) over a median follow up of 2.0 years.
Journal ArticleDOI
Long-Term Outcomes of Patients with Stroke Predicted by Clinicians to have no Chance of Meaningful Recovery: A Japanese Cohort Study
Satoshi Egawa,Jeremy Ader,Qi-Feng Shen,Shunsuke Nakagawa,Yoshihisa Fujimoto,Shuichi Fujii,Kenta Masuda,Akira Shirota,Masafumi Ota,Yuji Yoshino,Hitomi Amai,Satoru Miyao,Hidetoshi Nakamoto,Yasuhiro Kuroda,Kevin Doyle,Lauren Grobois,Athina Vrosgou,J Carmona Carmona,Angela Velazquez,Shivani Ghoshal,David Roh,Sachin Agarwal,Soo-Jin Park,Jan Claassen +23 more
Proceedings ArticleDOI
Utility and Feasibility of Simulation-based Training in Teaching Concepts of Traumatic Brain Management to Neurology Trainees (P8-2.001)
Eva Franzova,Greer Waldrop,Ifeyinwa Nwankwo,Jeremy Ader,Michelle Bell,Angela Velazquez,Sachin Agarwal,David Roh,Soo-Jin Park,Sander Connolly,Jan Claassen,Shivani Ghoshal +11 more
TL;DR: In this paper , a simulation-based training program for neurology residents to practice managing a patient presenting with acute TBI under the direct supervision of an expert in neurocritical care with opportunities for debriefing and feedback was developed.